Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease
暂无分享,去创建一个
B. Melchior | B. Hofilena | D. S. Herman | Bora Güner | L. Dellamary | S. Anderson | G. Mittapalli | J. Stewart | A. Tjitro | K. Sunil | Y. Yazici | Carolyn Lai | Karen X. Duong-Polk | Christopher J Swearingen | C. J. Swearingen | Christopher J. Swearingen | C. Swearingen
[1] J. Attems,et al. Phosphorylation of different tau sites during progression of Alzheimer’s disease , 2018, Acta Neuropathologica Communications.
[2] J. Cummings,et al. Alzheimer's disease drug development pipeline: 2018 , 2018, Alzheimer's & dementia.
[3] D. Praticò,et al. Antileukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice , 2018, Aging cell.
[4] B. Delatour,et al. DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives , 2018, Scientific Reports.
[5] C. Martínez-Cué,et al. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes , 2017, Neurobiology of Disease.
[6] T. Dunckley,et al. Dyrk1 inhibition improves Alzheimer's disease‐like pathology , 2017, Aging cell.
[7] L. Petrucelli,et al. An acetylation–phosphorylation switch that regulates tau aggregation propensity and function , 2017, The Journal of Biological Chemistry.
[8] J. Trojanowski,et al. Therapeutic strategies for the treatment of tauopathies: Hopes and challenges , 2016, Alzheimer's & Dementia.
[9] David S. Miller,et al. Tau: From research to clinical development , 2016, Alzheimer's & Dementia.
[10] L. Bodea,et al. Tau physiology and pathomechanisms in frontotemporal lobar degeneration , 2016, Journal of neurochemistry.
[11] A. Alonso,et al. Abnormal tau induces cognitive impairment through two different mechanisms: synaptic dysfunction and neuronal loss , 2016, Scientific Reports.
[12] P. Hof,et al. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies , 2016, Biomolecules.
[13] N. Kurabayashi,et al. DYRK1A overexpression enhances STAT activity and astrogliogenesis in a Down syndrome mouse model , 2015, EMBO reports.
[14] J. Bazureau,et al. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25–35 peptide administration in mice , 2015, European Neuropsychopharmacology.
[15] M. Clausen,et al. FDA-approved small-molecule kinase inhibitors. , 2015, Trends in pharmacological sciences.
[16] R. Xavier,et al. The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells , 2015, eLife.
[17] C. Oliveira,et al. A novel DYRK1A (Dual specificity tyrosine phosphorylation‐regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro , 2015, Journal of neurochemistry.
[18] J. Gestwicki,et al. Synthesis, stereochemical analysis, and derivatization of myricanol provide new probes that promote autophagic tau clearance. , 2015, ACS chemical biology.
[19] Sul-Hee Chung,et al. Phosphorylation and Inactivation of Glycogen Synthase Kinase 3β (GSK3β) by Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A)* , 2014, The Journal of Biological Chemistry.
[20] W. Becker,et al. DYRK1A: a potential drug target for multiple Down syndrome neuropathologies. , 2014, CNS & neurological disorders drug targets.
[21] Gabriel Gold,et al. Alzheimer disease therapy—moving from amyloid-β to tau , 2013, Nature Reviews Neurology.
[22] W. Becker,et al. Mechanism of dual specificity kinase activity of DYRK1A , 2013, The FEBS journal.
[23] Michel Goedert,et al. Tau pathology and neurodegeneration , 2013, The Lancet Neurology.
[24] Cornelia M. Wilson,et al. Tau protein kinases: Involvement in Alzheimer's disease , 2013, Ageing Research Reviews.
[25] S. Hébert,et al. Hypothermia-induced hyperphosphorylation: a new model to study tau kinase inhibitors , 2012, Scientific Reports.
[26] J. Kunitomo,et al. A novel glycogen synthase kinase‐3 inhibitor 2‐methyl‐5‐(3‐{4‐[(S )‐methylsulfinyl]phenyl}‐1‐benzofuran‐5‐yl)‐1,3,4‐oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer’s disease , 2011, Journal of neurochemistry.
[27] Meaghan Morris,et al. The Many Faces of Tau , 2011, Neuron.
[28] K. Chung,et al. Dyrk1A Positively Stimulates ASK1-JNK Signaling Pathway during Apoptotic Cell Death , 2011, Experimental neurobiology.
[29] J. Wegiel,et al. The role of DYRK1A in neurodegenerative diseases , 2011, The FEBS journal.
[30] C. Beaudry,et al. High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation , 2010, BMC Genomics.
[31] S. Nawoschik,et al. The JNK pathway amplifies and drives subcellular changes in tau phosphorylation , 2009, Neuropharmacology.
[32] Yi Li,et al. Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases , 2009, Journal of neurochemistry.
[33] J. Wegiel,et al. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[34] Hyun-Jeong Cho,et al. Dual‐specificity tyrosine(Y)‐phosphorylation regulated kinase 1A‐mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer’s disease , 2008, Journal of neurochemistry.
[35] D. Dias-Santagata,et al. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. , 2007, Molecular biology of the cell.
[36] Hyun-Jeong Cho,et al. DYRK1A-mediated Hyperphosphorylation of Tau , 2007, Journal of Biological Chemistry.
[37] I. Grundke‐Iqbal,et al. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration , 2007, The European journal of neuroscience.
[38] N. Plesnila,et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[39] I. Ferrer,et al. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models , 2005, Neurobiology of Disease.
[40] K. Chung,et al. Regulation of the proapoptotic activity of huntingtin interacting protein 1 by Dyrk1 and caspase‐3 in hippocampal neuroprogenitor cells , 2005, Journal of neuroscience research.
[41] I. Grundke‐Iqbal,et al. Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease , 2002, FEBS letters.
[42] J. Hardy,et al. Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.
[43] D. Rujescu,et al. Regulation of Alternative Splicing of Human Tau Exon 10 by Phosphorylation of Splicing Factors , 2001, Molecular and Cellular Neuroscience.
[44] Philip R. Cohen,et al. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. , 2001, The Biochemical journal.
[45] K. Titani,et al. Proline-directed and Non-proline-directed Phosphorylation of PHF-tau (*) , 1995, The Journal of Biological Chemistry.
[46] Jürgen Götz,et al. Amyloid-β and tau complexity — towards improved biomarkers and targeted therapies , 2018, Nature Reviews Neurology.
[47] Márcio Costa,et al. Protein Phosphorylation is a Key Mechanism in Alzheimer's Disease. , 2017, Journal of Alzheimer's disease : JAD.
[48] Fei Liu,et al. Tau and neurodegenerative disease: the story so far , 2016, Nature Reviews Neurology.
[49] Hemi Malkki,et al. Neurodevelopmental disorders: Altered epigenetic regulation in early development associated with schizophrenia , 2016, Nature Reviews Neurology.
[50] B. Dubois,et al. A phase II trial of tideglusib in Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.
[51] R. Xavier,et al. The kinase DYRK 1 A reciprocally regulates the differentiation of Th 17 and regulatory T cells , 2015 .
[52] A. Alonso,et al. Expression of Alzheimer-like pathological human tau induces a behavioral motor and olfactory learning deficit in Drosophila melanogaster. , 2013, Journal of Alzheimer's disease : JAD.
[53] Vijaya L. Melnick,et al. Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.